Takeda has sold selected prescription and OTC products to Acino covering its Near East, Middle East and Africa portfolio, as it looks to trim down its portfolio following the acquisition of Shire.
Takeda will become the latest company to base its operations within Massachusetts, after announcing it would leave its Deerfield, Illinois headquarters.
Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.
Shire says it will appeal a decision invalidating a patent surrounding the controlled-release composition of its ulcerative colitis drug Lialda (mesalazine).
AbbVie’s proposed £31bn ($50bn) takeover of Shire is very likely “dead” after the US biopharma's board changed its recommendation and advised shareholders not to back the bid.
UK-based drugmaker Shire has unveiled plans to buy Advanced BioHealing (ABH) citing the lack of generic competition in the regenerative medicines sector as a factor.
Shire and Noven Pharmaceuticals have announced the voluntary
withdrawal of a limited amount of Attention Deficit Hyperactivity
Disorder (ADHD) transdermal patches following reports of a
mechanical problem when applying the patch.
Shire Pharmaceuticals has acquired exclusive development rights to
a new transdermal patch product for Attention-Deficit/Hyperactivity
Disorder (ADHD), adding a further novel product to its ADHD
portfolio.
